Header Logo

Connection

James Mulshine to Antineoplastic Agents

This is a "connection" page, showing publications James Mulshine has written about Antineoplastic Agents.
Connection Strength

0.620
  1. Successful anti-cancer drug targets able to pass FDA review demonstrate the identifiable signature distinct from the signatures of random genes and initially proposed targets. Bioinformatics. 2008 Feb 01; 24(3):389-95.
    View in: PubMed
    Score: 0.255
  2. Growth factors and other targets for rational application as intervention agents. Adv Exp Med Biol. 1992; 320:81-8.
    View in: PubMed
    Score: 0.086
  3. A phase II trial of carboplatin (CBDCA) in small-cell and non-small-cell lung cancer with correlation to in vitro analysis of cytotoxicity. Am J Clin Oncol. 1990 Aug; 13(4):285-9.
    View in: PubMed
    Score: 0.078
  4. Developing CT image-processing tools to accelerate progress in lung cancer drug development. Oncology (Williston Park). 2006 Nov; 20(12):1606, 1608-10, 1614 passim.
    View in: PubMed
    Score: 0.060
  5. Lung cancer chemoprevention: moving from concept to a reality. Lung Cancer. 2003 Aug; 41 Suppl 1:S163-74.
    View in: PubMed
    Score: 0.048
  6. Lung cancer evolution to preinvasive management. Clin Chest Med. 2002 Mar; 23(1):37-48.
    View in: PubMed
    Score: 0.043
  7. Lung cancer: current therapies and new targeted treatments. Lancet. 2017 01 21; 389(10066):299-311.
    View in: PubMed
    Score: 0.030
  8. Treatment of non-small-cell lung cancer. J Clin Oncol. 1986 Nov; 4(11):1704-15.
    View in: PubMed
    Score: 0.015
  9. Second IASLC Workshop on Combined Radiotherapy and Chemotherapy Modalities in Lung Cancer. Biological basis of combined therapy. Lung Cancer. 1994 Mar; 10 Suppl 1:S3-5.
    View in: PubMed
    Score: 0.006
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.